BE1005908A5 - Vaccin a poxvirus recombinant contre le virus de la rougeole. - Google Patents
Vaccin a poxvirus recombinant contre le virus de la rougeole. Download PDFInfo
- Publication number
- BE1005908A5 BE1005908A5 BE9101066A BE9101066A BE1005908A5 BE 1005908 A5 BE1005908 A5 BE 1005908A5 BE 9101066 A BE9101066 A BE 9101066A BE 9101066 A BE9101066 A BE 9101066A BE 1005908 A5 BE1005908 A5 BE 1005908A5
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- virus
- dna
- glycoprotein
- measles virus
- Prior art date
Links
- 241000712079 Measles morbillivirus Species 0.000 title claims abstract description 128
- 108010008038 Synthetic Vaccines Proteins 0.000 title description 3
- 229940124551 recombinant vaccine Drugs 0.000 title description 3
- 241000700605 Viruses Species 0.000 claims abstract description 81
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 79
- 108020004414 DNA Proteins 0.000 claims abstract description 72
- 229960005486 vaccine Drugs 0.000 claims abstract description 57
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 45
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 45
- 241001465754 Metazoa Species 0.000 claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 241000712045 Morbillivirus Species 0.000 claims abstract description 23
- 230000028993 immune response Effects 0.000 claims abstract description 11
- 208000010772 Dog disease Diseases 0.000 claims abstract description 8
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 201000005505 Measles Diseases 0.000 claims description 55
- 230000004927 fusion Effects 0.000 claims description 48
- 230000006798 recombination Effects 0.000 claims description 30
- 238000005215 recombination Methods 0.000 claims description 27
- 241000178270 Canarypox virus Species 0.000 claims description 19
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 claims description 15
- 101900237959 Measles virus Hemagglutinin glycoprotein Proteins 0.000 claims description 8
- 241000700663 Avipoxvirus Species 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 52
- 239000013612 plasmid Substances 0.000 description 140
- 239000012634 fragment Substances 0.000 description 77
- 238000011081 inoculation Methods 0.000 description 67
- 108090000623 proteins and genes Proteins 0.000 description 65
- 206010046865 Vaccinia virus infection Diseases 0.000 description 60
- 208000007089 vaccinia Diseases 0.000 description 60
- 101710154606 Hemagglutinin Proteins 0.000 description 58
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 58
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 58
- 101710176177 Protein A56 Proteins 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 52
- 241000283973 Oryctolagus cuniculus Species 0.000 description 36
- 239000000185 hemagglutinin Substances 0.000 description 36
- 239000013598 vector Substances 0.000 description 36
- 238000000034 method Methods 0.000 description 33
- 238000010276 construction Methods 0.000 description 30
- 101150039660 HA gene Proteins 0.000 description 29
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 230000001629 suppression Effects 0.000 description 27
- 230000004044 response Effects 0.000 description 23
- 241000588724 Escherichia coli Species 0.000 description 22
- 210000003501 vero cell Anatomy 0.000 description 22
- 108010005774 beta-Galactosidase Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 17
- 230000003472 neutralizing effect Effects 0.000 description 17
- 241000700198 Cavia Species 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 230000029087 digestion Effects 0.000 description 16
- 238000001114 immunoprecipitation Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 102000004594 DNA Polymerase I Human genes 0.000 description 15
- 108010017826 DNA Polymerase I Proteins 0.000 description 15
- 230000007910 cell fusion Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000003780 insertion Methods 0.000 description 15
- 230000037431 insertion Effects 0.000 description 15
- 238000006386 neutralization reaction Methods 0.000 description 15
- 230000001681 protective effect Effects 0.000 description 15
- 230000000405 serological effect Effects 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000002238 attenuated effect Effects 0.000 description 13
- 102000005936 beta-Galactosidase Human genes 0.000 description 13
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 11
- 241000271566 Aves Species 0.000 description 10
- 101150034814 F gene Proteins 0.000 description 10
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 101150039990 B13R gene Proteins 0.000 description 6
- 101150060895 I4L gene Proteins 0.000 description 6
- 101150071286 SPI-2 gene Proteins 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 108020004440 Thymidine kinase Proteins 0.000 description 6
- 230000002008 hemorrhagic effect Effects 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 230000003141 anti-fusion Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000009589 serological test Methods 0.000 description 5
- 206010037742 Rabies Diseases 0.000 description 4
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 4
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 4
- 101150003725 TK gene Proteins 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010035148 Plague Diseases 0.000 description 3
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 description 3
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000006677 Appel reaction Methods 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101150082239 G gene Proteins 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 101100277251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM12 gene Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000287219 Serinus canaria Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229940024231 poxvirus vaccine Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012770 revaccination Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000004068 Morbillivirus Infections Diseases 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 101100310045 Mus musculus Sema4c gene Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001147385 Potos flavus Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62161490A | 1990-11-20 | 1990-11-20 | |
| US77686791A | 1991-10-22 | 1991-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1005908A5 true BE1005908A5 (fr) | 1994-03-08 |
Family
ID=27089007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE9101066A BE1005908A5 (fr) | 1990-11-20 | 1991-11-19 | Vaccin a poxvirus recombinant contre le virus de la rougeole. |
Country Status (12)
| Country | Link |
|---|---|
| JP (2) | JP3617668B2 (enExample) |
| AU (1) | AU1253892A (enExample) |
| BE (1) | BE1005908A5 (enExample) |
| CA (1) | CA2096633A1 (enExample) |
| CH (1) | CH683921A5 (enExample) |
| DE (2) | DE4192786B4 (enExample) |
| FR (1) | FR2669346B1 (enExample) |
| GB (2) | GB2283021B (enExample) |
| IE (2) | IE68404B1 (enExample) |
| IT (1) | IT1252687B (enExample) |
| NL (2) | NL195058C (enExample) |
| WO (1) | WO1992008789A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
| US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
| US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US5989561A (en) * | 1991-03-07 | 1999-11-23 | Virogenetics Corporation | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses |
| EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| AU674491B2 (en) * | 1991-03-20 | 1997-01-02 | Virogenetics Corporation | Recombinant poxvirus malaria vaccine |
| DE69233080T2 (de) * | 1991-06-14 | 2004-04-15 | Connaught Technology Corp., Greenville | Rekombinanter hiv-spezifischer impfstoff aus poxviru |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| CN1089370C (zh) * | 1994-12-08 | 2002-08-21 | 中国预防医学科学研究院病毒学研究所 | 表达麻疹病毒l4株血凝素及融合蛋白基因的重组痘苗病毒 |
| AU2118997A (en) * | 1996-02-05 | 1997-08-22 | Johns Hopkins University, The | Measles immunization by dna transcription unit inoculation |
| WO1998050047A1 (en) | 1997-05-09 | 1998-11-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| EP1095948A1 (en) * | 1999-10-28 | 2001-05-02 | Universitätsklinikum Freiburg | Idiotype vaccines |
| CN100446812C (zh) * | 2001-03-08 | 2008-12-31 | 美国国有健康与人类服务部 | 表达修饰的hiv包膜、gag和pol基因的mva |
| AR052743A1 (es) * | 2006-04-11 | 2007-03-28 | Inst Nac De Tecnologia Agropec | Vector plasmidico de transferencia y virus canarypox recombinante |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0305229A1 (fr) * | 1987-07-07 | 1989-03-01 | Transgene S.A. | Vecteur viral et ADN recombinant codant pour une ou des protéines de structure (HA, F et/ou NP), d'un morbillivirus. |
| EP0314569A1 (fr) * | 1987-10-29 | 1989-05-03 | Transgene S.A. | Virus du fowlpox recombinant, vecteurs d'expression de protéines héterologues et vaccins pour la volaille dérivés de ce virus |
| EP0330781A1 (en) * | 1988-02-29 | 1989-09-06 | Toa Nenryo Kogyo Kabushiki Kaisha | Vaccine against rinderpest virus using recombinant vaccinia virus |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
-
1991
- 1991-11-13 IE IE396091A patent/IE68404B1/en not_active IP Right Cessation
- 1991-11-13 IE IE960091A patent/IE71643B1/en not_active IP Right Cessation
- 1991-11-19 BE BE9101066A patent/BE1005908A5/fr not_active IP Right Cessation
- 1991-11-19 FR FR9114256A patent/FR2669346B1/fr not_active Expired - Lifetime
- 1991-11-20 DE DE4192786A patent/DE4192786B4/de not_active Expired - Lifetime
- 1991-11-20 NL NL9120026A patent/NL195058C/nl not_active IP Right Cessation
- 1991-11-20 IT ITMI913092A patent/IT1252687B/it active IP Right Grant
- 1991-11-20 WO PCT/US1991/008703 patent/WO1992008789A1/en not_active Ceased
- 1991-11-20 CH CH2364/92A patent/CH683921A5/fr not_active IP Right Cessation
- 1991-11-20 GB GB9500214A patent/GB2283021B/en not_active Expired - Lifetime
- 1991-11-20 AU AU12538/92A patent/AU1253892A/en not_active Abandoned
- 1991-11-20 GB GB9309414A patent/GB2264949B/en not_active Expired - Lifetime
- 1991-11-20 DE DE4192786T patent/DE4192786T1/de active Pending
- 1991-11-20 CA CA002096633A patent/CA2096633A1/en not_active Abandoned
- 1991-11-20 JP JP50520492A patent/JP3617668B2/ja not_active Expired - Fee Related
-
2003
- 2003-07-15 NL NL9900036A patent/NL195095C/nl not_active IP Right Cessation
-
2004
- 2004-06-09 JP JP2004170929A patent/JP3824619B2/ja not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0305229A1 (fr) * | 1987-07-07 | 1989-03-01 | Transgene S.A. | Vecteur viral et ADN recombinant codant pour une ou des protéines de structure (HA, F et/ou NP), d'un morbillivirus. |
| EP0314569A1 (fr) * | 1987-10-29 | 1989-05-03 | Transgene S.A. | Virus du fowlpox recombinant, vecteurs d'expression de protéines héterologues et vaccins pour la volaille dérivés de ce virus |
| EP0330781A1 (en) * | 1988-02-29 | 1989-09-06 | Toa Nenryo Kogyo Kabushiki Kaisha | Vaccine against rinderpest virus using recombinant vaccinia virus |
Non-Patent Citations (2)
| Title |
|---|
| SCIENCE vol. 242, 18 Novembre 1988, LANCASTER, PA US pages 1058 - 1061 YILMA, T. ET AL. 'Protection of cattle against Rinderpest with vaccinia virus recombinants expressing the Ha or F gene' * |
| VIROLOGY vol. 187, no. 1, 1992, pages 321 - 328 TAYLOR, J. ET AL. 'Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (ha) glycoproteins' * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE4192786B4 (de) | 2006-08-24 |
| NL195095C (nl) | 2004-01-21 |
| FR2669346A1 (fr) | 1992-05-22 |
| GB2283021A (en) | 1995-04-26 |
| ITMI913092A0 (it) | 1991-11-20 |
| NL9120026A (nl) | 1993-09-01 |
| NL195058C (nl) | 2003-07-01 |
| GB9500214D0 (en) | 1995-03-01 |
| DE4192786T1 (de) | 1994-01-13 |
| ITMI913092A1 (it) | 1993-05-20 |
| JPH06502996A (ja) | 1994-04-07 |
| AU1253892A (en) | 1992-06-11 |
| IE71643B1 (en) | 1997-02-26 |
| CH683921A5 (fr) | 1994-06-15 |
| IE913960A1 (en) | 1992-05-20 |
| GB9309414D0 (en) | 1993-07-14 |
| NL9900036A (nl) | 2003-10-01 |
| IT1252687B (it) | 1995-06-23 |
| WO1992008789A1 (en) | 1992-05-29 |
| JP3824619B2 (ja) | 2006-09-20 |
| GB2264949A (en) | 1993-09-15 |
| IE68404B1 (en) | 1996-06-12 |
| CA2096633A1 (en) | 1992-05-21 |
| GB2264949B (en) | 1995-07-05 |
| JP2005040129A (ja) | 2005-02-17 |
| JP3617668B2 (ja) | 2005-02-09 |
| FR2669346B1 (fr) | 1995-07-21 |
| GB2283021B (en) | 1995-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU711472B2 (en) | Recombinant poxvirus-rabies compositions and combination compositions and uses | |
| US6309647B1 (en) | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants | |
| EP0956360B1 (en) | Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses | |
| FR2669346A1 (fr) | Vaccin a poxvirus recombinant contre le virus de la rougeole. | |
| US6180398B1 (en) | Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation | |
| WO1997049825A1 (fr) | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 | |
| FR2647808A1 (fr) | Poxvirus recombinant et vaccin contre le virus de l'herpes contenant ce poxvirus | |
| JPH11506614A (ja) | 組換えアライグマポックスウイルス、およびネコ免疫不全症ウイルス感染症に対する有効なワクチンとしてのその使用 | |
| EP0162757B1 (fr) | Vaccin contre la rage et procédé pour sa préparation | |
| Calvert et al. | Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens | |
| AU724172B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
| US5503834A (en) | Measles virus recombinant poxvirus vaccine | |
| CA2127700C (en) | Marek's disease virus recombinant poxvirus vaccine | |
| US5759841A (en) | Immunological composition of measles virus utilizing recombinant poxvirus | |
| AU699903B2 (en) | Measles virus recombinant poxvirus vaccine | |
| Gebreeziabher | Development of Dual vaccines for the control of Peste des petits ruminants and Capripox infections of Small Ruminants | |
| CA2187207C (en) | Poxvirus-canine distemper virus (cdv) recombinants and compositions and methods employing the recombinants | |
| AU720448B2 (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
| AU769221B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
| Hu | Development of raccoon poxvirus-vectored feline recombinant vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: *VIROGENETICS CORP. Effective date: 20111119 |